Synermore Biologics Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Taipei Taiwan (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2015
NCT02391727
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Synermore Biologics Co., Ltd. | Synermore Biologics (Suzhou) Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis, Rheumatoid (Phase 1)

Breast Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 1)

Communicable Diseases (Phase 3)

Head and Neck Neoplasms (Phase 1)

Infections (Phase 3)

Mononegavirales Infections (Phase 3)

Neoplasms (Phase 1)

Rabies (Phase 3)

Rhabdoviridae Infections (Phase 3)

RNA Virus Infections (Phase 3)

Virus Diseases (Phase 3)

Zoonoses (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7